Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke

Last updated: July 4, 2021
Sponsor: Peking University Third Hospital
Overall Status: Completed

Phase

4

Condition

Stroke

Cerebral Ischemia

Treatment

N/A

Clinical Study ID

NCT04962451
D2017121
  • Ages > 40
  • All Genders

Study Summary

Cerebrovascular disease is the main cause of death and severe long-term disability worldwide. Antiplatelet drugs are the main drugs for ischemic stroke and TIA. Cyclooxygenase inhibitor acetylsalicylic acid (ASA) has always been the most widely studied antiplatelet therapy. The studies of acrates of aliscon body evaluated the efficacy and safety of ticagrelor monotherapy in preventing major vascular events in patients with AIS or TIA. The results showed that the number of patients with endpoint events in ticagrelor group was less than that in ASA group, However, it has not been proved that ticagrelor monotherapy is better than ASA. The purpose of this study is to prove that ticagrelor is better than ASA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Over 40 years old
  2. Acute ischemic attack
  3. Symptoms occurred within 24 hours after randomization

Exclusion

Exclusion Criteria:

  1. Dual antiplatelet therapy with ASA and P2Y12 inhibitors is needed
  2. Antiplatelet agents other than ASA
  3. Anticoagulant therapy
  4. Have any atrial fibrillation / flutter
  5. Renal failure requiring dialysis
  6. During pregnancy or lactation

Study Design

Total Participants: 13000
Study Start date:
September 01, 2017
Estimated Completion Date:
October 31, 2019

Study Description

Cerebrovascular disease is the main cause of death and severe long-term disability worldwide. Antiplatelet drugs are the main drugs for ischemic stroke and TIA. Cyclooxygenase inhibitor acetylsalicylic acid (ASA) has always been the most widely studied antiplatelet therapy. The studies of acrates of aliscon body evaluated the efficacy and safety of ticagrelor monotherapy in preventing major vascular events in patients with AIS or TIA. The results showed that the number of patients with endpoint events in ticagrelor group was less than that in ASA group, However, it has not been proved that ticagrelor monotherapy is better than ASA. The purpose of this study is to prove that ticagrelor is better than ASA. The study will be designed as a randomized, double-blind, placebo-controlled, parallel grouping study and conducted in multiple centers to ensure the representation of multiple countries, races and races, so as to ensure that the results of the study can be widely applied.

Connect with a study center

  • Peking University Third Hospital

    Beijing,
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.